Clara Duran Castells
Clara Duran graduated with a degree in Biotechnology from the University of Vic-Central University of Catalonia (UVIC-UCC) in 2017, completing her undergraduate final project at Dr. Christian Brander’s group at IrsiCaixa. She obtained a master’s in Advanced Immunology from the University of Barcelona (UB)-Autonomous University of Barcelona (UAB) in 2018, where she also took an animal handling course in order to be able to complete her final project focused on immunonutrition and immunopharmacology.
She has been with IrsiCaixa since September 2016 and is currently a pre-doctoral member of Dr. Christian Brander’s group, where her focus is a neuroinflammation project.
Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.
Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections.
TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses.
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control.
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.